Arca Biopharma intends to price public sale of its shares and warrants

Offering conducted by sole bookrunning manager Dawson James Securities

By Devika Patel

Knoxville, Tenn., Feb. 3 - Arca Biopharma, Inc. said it plans to sell common shares and five-year warrants in a public offering.

The stock and warrants will be sold in units of one share and a quarter-share warrant.

Dawson James Securities, Inc. is the sole bookrunning manager.

Proceeds will be used for general corporate purposes, including clinical trials, research and development expenses and general and administrative expenses.

Arca is a Broomfield, Colo., biopharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.